Printer Friendly

Squamous Cell Carcinoma Variants of the Upper Aerodigestive Tract: A Comprehensive Review With a Focus on Genetic Alterations.

Squamous cell carcinoma of the upper aerodigestive tract is not a single, distinct entity. Several variant histologic patterns are recognized, and some of which have unique prognoses and are associated with unique risk factors. As far as molecular and cytogenetic changes go, the greatest differences between those lesions are seen due to etiology, with virally related tumors, human papillomavirus (HPV)-associated squamous cell carcinoma and Epstein-Barr virus (EBV)-associated squamous cell carcinoma, differing from nonviral (typically related to tobacco and alcohol) tumors.

HUMAN PAPILLOMAVIRUS-ASSOCIATED SQUAMOUS CELL CARCINOMA

During the past decade, molecular and epidemiologic studies have demonstrated a causal relationship between HPV and a subset of head and neck squamous cell carcinomas. (1-4) These HPV-associated squamous cell carcinomas represent distinct clinical entities because they often portend a better prognosis than the traditional smoking-and alcohol-related squamous cell carcinomas. (5) The epidemiology of these tumors also varies from the non-HPV-associated tumors. (2) These tumors tend to occur in patients who are younger (usually younger by about 5-10 years) and who, on average, have had a greater number of sexual partners, including oral sexual partners. (1,2,6-8) Men develop these tumors more often than women do, and the tumors develop more frequently in blacks. (1,2,6-8)

The HPV-associated squamous cell carcinomas of the upper aerodigestive tract can occur anywhere; however, most occur within the oropharynx, especially at the base of tongue or in the palatine tonsils. (1-3) These tumors have also been noted in the sinonasal tract, oral cavity, nasopharynx, hypopharynx, and larynx. (3,8-11) The HPV-associated oropharyngeal tumors often present at a higher clinical stage with advanced nodal disease, despite being of lower T category (primary tumor size). (1,2) Despite this advanced clinical stage, the prognosis and overall disease-free survival of patients with these tumors are superior to that of patients with non-HPV-associated tumors. (1,2)

Because oropharyngeal tumors metastasize early, patients frequently present with neck metastases. (12-14) These neck metastases can become quite large with cystic degeneration and can sometimes be a diagnostic pitfall for the pathologist on both frozen section and fine-needle aspirates. When a diagnosis of metastatic squamous cell carcinoma in a cervical lymph node is made, a prompt clinical evaluation for the presence of an oropharyngeal primary is needed. (15) However, these primary oropharyngeal tumors are sometimes grossly evasive, and "blind" pharyngeal biopsies from patients with clinically apparent neck metastases will frequently identify microscopic, invasive squamous cell carcinomas. Sometimes, no primary tumor is identified, which, likely, is secondary to the lack of sampling of the single microscopic focus of tumor. (16)

The HPV-related squamous cell carcinomas have a varied, yet histologically distinct, morphologic phenotype. (5,15) Despite the many techniques now in use and continually being developed for detecting HPV-associated tumors, the initial assessment of these tumors begins with a thoughtful morphologic approach. (17) Most of these tumors are non-keratinizing squamous cell carcinomas (Figure 1) and are sometimes described as having a basaloid phenotype. Some authors (9,17-19) argue that the use of the descriptive term basaloid can be misleading because that implies a specific tumor subtype, basaloid squamous cell carcinoma, which has an aggressive course and is not always associated with HPV. As a result, discussions are currently emerging on how all HPV-associated tumors should be reported, and a unified scheme will likely prevail in the future. Undifferentiated and papillary squamous cell carcinomas of the upper aerodigestive tract are also sometimes associated with HPV infection. (5,20,21) Uncommonly, glandular or neuroendocrine differentiation in the form of small cell carcinoma can be seen with these tumors. (22,23) Recognition of a small cell carcinoma component is important because these tumors have been shown to have poorer outcomes, despite their association with HPV. (23)

The HPV-related squamous cell carcinomas of the upper aerodigestive tract are immunoreactive with antibodies to cytokeratins and p63, which is similar to other squamous cell carcinomas. The most notable exceptions include the expression proteins specifically related to the molecular workings of HPV. Overexpression of p16 can be identified by immunohistochemistry (IHC) in virtually all head and neck squamous cell carcinomas associated with HPV infection, making it a useful surrogate marker for the detection of HPV (Figure 2, A). (24) In these tumors, p16 is overexpressed secondary to depletion of the retinoblastoma protein by the HPV-generated E7 protein. (1,24) Cyclin D1 is also down-regulated with decreased retinoblastoma protein. Protein p53 expression, on the other hand, cannot always be demonstrated by IHC with HPV-associated tumors because their genes are usually wild type, and instead, the protein is inhibited by the viral E6 protein. (1,24)

Human papillomavirus has been identified in head and neck squamous cell carcinomas by polymerase chain reaction (PCR) and in situ hybridization (ISH) (Figure 2, B). (25,26) The E6 and E7 transcripts have been identified by reverse transcription-polymerase chain reaction (RT-PCR), ISH, and Northern blot analysis. (25,26) Each method of detection has its advantages and limitations, and there is no consensus on the particular method to be employed by clinical laboratories. (24) Many researchers advocate for p16 IHC use during initial screening, followed by more-specific detection methods for high-risk HPV subtypes, such as ISH. (24)

According to the results of several studies, (5,27-30) patients with HPV-associated squamous cell carcinomas have better outcomes than do those with nonviral-related tumors. Future clinical trials will be aimed at deintensified treatment regimens for these tumors. Currently, patients are typically treated with induction chemotherapy, followed by surgery or chemoradiation. Patients with HPV-associated tumors are more likely to demonstrate substantial response to induction chemotherapy and, thus, are more likely to be eligible for chemoradiation and organ preservation, (31,32) although some patients may still require surgery. In addition, new methods of treatment are being devised that use novel therapeutic vaccines. (1,33) Published data regarding the utility of vaccine prevention for HPV oral lesions are currently lacking, but, hopefully, the advent of a preventative vaccination will affect head and neck cancers. (2,33)

EPSTEIN-BARR VIRUS-ASSOCIATED SQUAMOUS CELL CARCINOMAS

Epstein-Barr virus (EBV)-associated squamous cell carcinomas usually involve the nasopharynx. The pathogenesis of these tumors is complex. Infection with EBV is essential; however, given the rather ubiquitous nature of EBV, infection alone does not account for the marked regional differences in the incidence of these tumors (eg, individuals in China are more than 4 times more likely to develop tumors than are individuals in the United States). (34-37) Thus, both environmental (eg, nitrosamine from salted fish and preserved food) and genetic factors may be involved in the development of the disease. Consistent evidence for the latter has been reported for HLA class I genes, DNA repair gene RAD51L1, cell cycle control genes MDM2 and TP53, and cell adhesion/migration gene MMP2. (38-39)

The EBV-associated squamous cell carcinomas occur in a broad age range and sometimes affect children. There is a distinct bimodal age distribution with peaks in the second and sixth decades. (40-42) The tumors show a male predilection of approximately 2.5 to 1. As mentioned, almost all occur in the nasopharynx with a high percentage arising near the eustachian tube opening in the fossa of Rosenmiiller. Not surprisingly then, presenting symptoms are often related to middle ear obstruction with serous otitis and associated hearing loss. Local invasion may result in headaches, cranial nerve deficits, or epistaxis. (40,41,43) Importantly, approximately one-half the patients will have clinically apparent, often bilateral, cervical lymph node metastases as a presenting sign or symptom, with a much less obvious or clinically occult nasopharyngeal primary. (40,43)

Because these tumors are virtually never resected, gross descriptions of primary lesions are rare. Lymph nodes replaced by metastases have a uniform, pale-tan, lymphoma-like appearance. Histologically, the tumors are almost always nonkeratinizing and are frequently undifferentiated. They are characterized microscopically by cytologically uniform cells with vesicular, round to oval nuclei and medium-sized nucleoli. Mitotic figures are typically numerous, usually ranging from 5 to 10 per 10 high-power fields. (44) When the neoplastic cells grow in cohesive nests, the cell borders between adjacent cells are indistinct, creating a syncytial appearance. As mentioned, keratinization or squamous "pearl" formation is only rarely present. An inflammatory infiltrate, primarily consisting of lymphocytes and plasma cells but occasionally with prominent eosinophils, is typically present. (45,46) Two microscopic growth patterns have been identified in these neoplasms and bear eponyms derived from their describers. (47,48) In the differentiated or Regaud pattern, the neoplastic cells form cohesive nests and cords sharply distinct from the surrounding inflammation (Figure 3, A), which is usually readily identified as a carcinoma. (44) In the undifferentiated or Schmincke pattern, the inflammatory infiltrate permeates the cell nests, resulting in smaller nests of epithelial cells that are more widely separated, as well as single neoplastic cells in a background of inflammation. The result appears distinctly noncarcinomatous and is often confused with lymphoma on initial light microscopic examination (Figure 3, B). (44,49,50) This explains this tumor's previous designation as lymphoepithelioma or lymphoepithelioma-like carcinoma.

Although difficult to distinguish from lymphoma, melanoma, or other poorly differentiated malignancies by histology alone, the advent of sensitive and specific IHC markers for both epithelial and hematolymphoid differentiation has been the greatest factor in improving the diagnostic ease and accuracy of EBV-associated squamous cell carcinomas. (49-60) It is especially important to distinguish these carcinomas from sinonasal undifferentiated carcinoma, which is a highly aggressive, non-EBV-related malignancy with a dismal prognosis.

The EBV-associated squamous cell carcinomas strongly express cytokeratins and epithelial membrane antigen. (54-58,60) Furthermore, antibodies to squamous antigens, such as p63, are also immunoreactive. (61) Evidence of EBV can be demonstrated by both IHC and ISH. (36,62-67) Immunohistochemistry with antibodies to LMP1 tends to be insensitive, and most pathologists use ISH for EBV-encoded early RNA for the identification of these tumors. These RNAs are typically expressed in abundance, and nearly 100% of tumors will have obvious hybridization.

The tumors have a "methylator" phenotype. (68) Cyclin D1 overexpression, loss of pl6, and inactivation of RASSF1A are key events in the early development of EBV-associated squamous cell carcinomas. (68) Immortalization of the cells may occur via disruption of the p53 and Rb pathways. The p53 and RB mutations are rare; however, chromosomal losses and gains identified with comparative genomic hybridization include losses at 3p14-21, 14q24-qter, and 11q21-qter and gains at 3q21-26 and 12q14-15. (69-72) The EBV latent gene proteins further drive clonal expansion and other genetic changes, such as TSLC1 and THY1, add to progression and metastasis of the tumor. (39)

Recent studies have suggested an improved prognosis for these tumors compared with nonviral-related tumors. Radiotherapy with or without chemotherapy remains the backbone of treatment. Because these tumors are highly radiosensitive, radiotherapy alone can result in a 5-year survival of up to 95% for early stage disease. Concurrent chemoradiation therapy remains the standard of care for locoregionally advanced disease, providing a 5-year overall survival rate of 50% to 70%. After treatment, EBV DNA levels have been shown to be a powerful biomarker for monitoring recurrence with improved accuracy over positron emission tomography for surveillance. New treatment options, which include monoclonal antibodies, proton beams, and adaptive radiotherapies among others, are currently under investigation. (73,74)

VERRUCOUS CARCINOMA

Verrucous carcinomas are well-differentiated squamous cell neoplasms that lack conventional cytologic features of malignancy but exhibit locally destructive growth. The tumor was first recognized by Lauren Ackerman in 1948 as a distinct, diagnostically problematic squamous cell neoplasm involving the oral cavity. (75,76) Therefore, many authors refer to this lesion using the eponym Ackerman tumor. (77-79) Overall, these tumors account for about 1% of squamous neoplasms involving the head and neck region. They show a strong association with tobacco product usage, especially oral tobacco when the tumors arise in the mouth. (80) Alcohol use and poor oral hygiene represent additional risk factors. Several studies have suggested a potential role for HPV as a cofactor in tumor development based on its detection in tissue specimens. (10,81-83) However, HPV also has been detected by PCR in 25% of normal larynges, and a causal role has not yet been clearly demonstrated. (84) Also of note, although strains of the virus have been demonstrated by PCR and Southern blot inconsistently, they have generally not been identified by more-specific methods, such as ISH. (81,83,85-90)

Verrucous carcinomas typically develop in an individual's sixth to eighth decade. (76,77,79,91-95) The tumors are uncommon in patients younger than 40 years and arise more frequently in men. (76-78,92,96) They arise most commonly in the oral cavity and the larynx, and at those sites, most of the tumors often involve the buccal mucosa and vocal cords. * These tumors are slowly growing neoplasms, and they may reach considerable size before being brought to medical attention.

Grossly, the tumors are tan to grey, rough, bulky exophytic masses with a shaggy or overtly papillary, wartlike surface. (96) After sectioning the tumor, the margin of invasion is sharp and pushing. Application of strict morphologic criteria is essential for the diagnosis of verrucous carcinoma because true verrucous carcinomas have no metastatic potential. Histologically, these tumors are characterized by dense, superficial keratinization, often forming "church spires" of orthokeratotic and parakeratotic squamous cells extending upward from the surface (Figure 4, A). (97) Neoplastic cells typically have vesicular nuclei with small nucleoli. Nuclear pleomorphism is absent or minimal and mitotic activity is confined to the basal cell layer. (97) Cells have abundant eosinophilic cytoplasm, which generally undergoes uniform keratinization as the cells migrate toward the surface. Individual cell keratinization (dyskeratosis) and keratin pearl formation may be focally present. At the base of the lesion, down-growth is in the form of broad, bulbous, sharply demarcated ridges of well-differentiated, benign-appearing squamous cells that appear to "push" rather than infiltrate (Figure 4, B). Lymphoplasmacytic infiltrates or foreign body-type granulomas may be found at the base of the tumor. Infiltration by small, irregular nests of cells, vascular invasion, and perineural invasion are not allowed. If seen, the tumor should instead be classified as a conventional squamous cell carcinoma with verrucoid features.

Verrucous carcinoma exhibits characteristic cell kinetics that are more akin to those of normal mucosa than they are to conventional squamous cell carcinoma. (100,102-105) In particular, DNA synthesis (S-phase) is confined to the basal cell layer, along with the more conventionally detected mitotic activity. The lack of S-phase cells above the basal cell layer is quite unlike the findings in conventional squamous cell carcinomas. (100,103,104) Verrucous carcinomas may be diploid or aneuploid. (104,106)

In the Choi et al (107) analysis of microsatellite markers in head and neck squamous cell carcinomas, verrucous carcinomas showed similar losses when compared with conventional, well-differentiated squamous cell carcinomas. Verrucous carcinomas showed high incidences of loss of heterozygosity of markers on chromosome 9 and lower incidences of marker losses on chromosomes 3, 8, and 17, when compared with other variants. Poh et al (108) found less allelic loss at 17p when verrucous carcinomas were compared with conventional, well-differentiated squamous cells carcinomas. Verrucous carcinomas have been shown to harbor H-ras mutations in 25% of cases tested with different staining patterns and antibodies to Raf-1, ERK1, and ERK2, when compared with conventional squamous cell carcinomas. (109,110) Overexpression of p53, cyclin D1, p21, MDM2, and c-erb-3 has been shown by IHC, although the findings are more akin to well-differentiated squamous cell carcinomas and even hyperplastic lesions. (105,111-114) Retinoblastoma protein has been shown to be normally expressed. (111) Promoter methylation of p16 and MGMT has also been noted. (115) [beta]-Catenin expression is strong and membranous, akin to that seen with normal squamous epithelium or welldifferentiated squamous cell carcinomas. (116)

Surgical resection without neck dissection is the treatment of choice for pure verrucous carcinomas because, by definition these tumors lack nodal metastases. (82,117) Radiotherapy and radiochemotherapy represent treatment options for patients with inoperable verrucous carcinoma or as an alternative to surgical resection. (117-121) Interestingly, topical 5-aminolevulinic acid-mediated phototherapy has reportedly been successfully used for treatment of an extraoral verrucous carcinoma with no recurrence at 6-month follow-up. (122)

SPINDLE CELL CARCINOMA

The spindle cell carcinoma variant of squamous cell carcinoma is characterized microscopically by a prominent sarcoma-like spindle cell growth, often with a minor component of conventional squamous cell carcinoma or carcinoma in situ. These carcinomas of the head and neck are strongly associated with alcohol use, cigarette smoking, or use of other tobacco products. (123,124) Some patients with spindle cell carcinomas, particularly outside of the larynx, have had a history of radiation therapy, often for conventional squamous cell carcinoma, raising the possibility of radiation-induced neoplasia or transformation. (123,125,126)

Clinical features are similar to those of their conventional squamous counterparts with the exception that many spindle cell carcinomas present at low stage and are thus less likely to present with metastatic disease. (123-138) Complaints are nonspecific and related to tumor location. Common sites of involvement include the larynx, oral cavity, hypopharynx, and sinonasal tract. (130,139) Most laryngeal cases are glottic or transglottic. (126) Spindle cell carcinomas show a male predominance, and the average age of presentation is around 60 years. ([dagger])

Most spindle cell carcinomas are polypoid. (124,126,130,133,134) Lesions may range from 1 to 6 cm, with polypoid lesions tending to be larger. (123) The surface may be intact or ulcerated and covered with a fibrinopurulent exudate. On sectioning, the mass is typically firm and tan or white. The spindle cell element almost always predominates and varies considerably in its microscopic appearance (Figure 5, A). (133) Most tumors are low to moderately cellular and have a storiform growth pattern, although a more-fascicular or "solid" appearance may predominate. Areas of overt osteoid or cartilage formation by neoplastic cells are sometimes seen. (125,126) Multinucleated giant cells are frequently found, most of which are malignant; however, occasional cases have interspersed osteoclast-like giant cells. Necrosis is unusual. Overtly squamous elements may be abundant and evenly distributed throughout the tumor. Most often, however, they are a minor component in an overwhelmingly sarcoma-like neoplasm.

In the Thompson et al (126) study of 187 laryngeal spindle cell carcinomas, 68% of cases showed immunoreactivity for antibodies against epithelial antigens within the spindle cell components of the tumor. The immunoreactivity was inconsistent, with antibodies to different cytokeratins, and no single antibody identified more than 41% of the cases. A potentially confusing factor about the immunohistochemical findings in spindle cell carcinomas is the occasional presence of myogenous markers in the neoplasms. (126) Antibodies to p63 can be helpful with the diagnosis of head and neck spindle cell carcinoma because most cases are immunoreactive (Figure 5, B). (140) A recent clinicopathologic review (141) of 103 cases confirmed the findings of Thompson et al.

Molecular and cytogenetic findings have largely been used to prove the clonal nature of both the spindle cell and squamous components of this neoplasm. Overexpression and mutations of p53 are common and correlate well with the spindle and epithelial components of these tumors. (142,143) Most tumors are nondiploid, which again correlates with both the spindle cell and epithelial components of the tumors. (138,144) Finally, comparative genomic hybridization studies have shown homology in chromosomal aberrations between the 2 components of the tumors. (145)

Choi et al (146) used microdissection and loss of heterozygosity studies of 9 microsatellite markers to show that the spindle cell component of spindle cell carcinomas appears to represent progression from the epithelial component. Spindle cell components frequently showed greater loss of heterozygosity, especially for a focus on band 17p. In a later study, Choi et al (107) investigated 21 microsatellite markers in 48 upper aerodigestive tract squamous cell carcinoma variants. In that later study, spindle cell carcinomas had a greater loss of heterozygosity for markers on chromosomes 4 and 9, compared with other squamous cell carcinoma variants. Some researchers suggest these tumors illustrate the so-called epithelial-mesenchymal transition that occurs with epithelial malignancies as they become more aggressive and capable of metastasis. Spindle cell carcinomas do show increased expression of N-cadherin by IHC. (147)

In the Thompson et al (126) study, the overall 5-year survival of patients with laryngeal spindle cell carcinoma was 59%. Survival was related to T stage (5-year dead of disease rate for T1, 23%; T2, 36%; T3, 57%; and T4, 67%). Also, patients with tumors that lacked immunoreactivity with antibodies to epithelial antigens fared worse. In contrast to the Thompson et al (126) finding that the lung was the most common site for metastasis, Viswanathan et al (141) reported lymph node metastasis to be most common. Interestingly, patients treated with radiation and surgery fared worse than those treated with surgery alone. The meaning of that is unclear because several clinical confounders likely had some influence.

ACANTHOLYTIC ("ADENOID" AND "ANGIOSARCOMA-LIKE") SQUAMOUS CELL CARCINOMA

The acantholytic microscopic variant of squamous cell carcinoma is characterized by extensive acantholysis resulting in pseudoglandular or pseudovascular spaces. It was first recognized in the skin by Lever, (149) and most often, tumors involve sun-exposed regions, including the skin of the head and neck. (148-150) Mucosal head and neck lesions have been documented involving the lip, oral cavity, tongue, larynx, sinonasal tract, and nasopharynx. (151-161) This change may be seen focally in otherwise typical squamous cell carcinomas from any anatomic site but rarely dominates the microscopic appearance. Acantholytic change might be caused by radiation therapy. (153) The tumors occur much more frequently in men. (159,162)

The gross findings are nonspecific. Oral cavity lesions have been described as ulcerated, nodular, indurated, warty, exophytic, keratotic, or crusted. (162) Tumors often measure several centimeters, with a tan or tan-white cut surface. (155) These tumors are composed of alveolar or glandlike spaces lined by a peripheral layer of flattened, cuboidal, or "hobnail" neoplastic cells (Figure 6). Exfoliated single cells and cell aggregates are present within the lumenlike spaces. (155) Occasionally, the spaces form complex, anastomosing, sinusoidal channels. (150,163) The nuclei of the neoplastic cells are pleomorphic and are often hyperchromatic with occasional giant or multinucleated cells. Cytoplasm varies from scant to prominent and, when present, is typically eosinophilic. Small, pearllike aggregates of cohesive, overtly squamous cells may be present within the lumenlike spaces, and larger areas of overt squamous differentiation may also be seen. (150) Mitotic figures are frequently encountered.

Immunohistochemical studies of these neoplasms in the oral cavity, as well as analogous tumors involving the skin and lung, have shown strong reactivity for the epithelial markers cytokeratin and epithelial membrane antigen. (162-164) Tumors are typically immunoreactive to p63 antibodies as well. (165) The tumors are nonreactive for markers of endothelial differentiation, including CD34, CD31, and factor Vlll-related antigens.

Labial tumors have been associated with a good prognosis. In a literature review of 26 adenoid squamous cell carcinomas predominately from the lips, 20 patients (77%) were free of disease, 3 (12%) had died of disseminated disease, and 3 (12%) were lost to follow-up. (162) Other mucosal sites, however, fare worse. (159,160) Favorable prognosis for tumors of the lips may be primarily due to the relative ease of diagnosis at that location, rather than to any inherent biologic differences in this morphologic subtype. The pattern of disease spread is also analogous to that of conventional squamous cell carcinoma and is dominated by involvement of regional lymph nodes early in the clinical course, with distant dissemination occurring later. The treatment and follow-up for patients with these tumors mimics that of conventional squamous cell carcinoma.

ADENOSQUAMOUS CARCINOMA

Adenosquamous carcinoma is an unusual carcinoma of the head and neck that contains components of adenocarcinoma and squamous cell carcinoma in close proximity. Although previously considered by some to be synonymous with mucoepidermoid carcinoma, the tumor can and should be distinguished from the latter neoplasm. Adenosquamous carcinoma is typically high grade and lacks microscopic and cytogenetic features of mucoepidermoid carcinoma. The tumor is thought to arise from the surface epithelium, which often displays high-grade dysplasia. (166,167)

Most cases of adenosquamous carcinoma arise in men, and the mean patient age is older than 60 years. (166) Most cases involve the larynx, but any site within the upper aerodigestive tract can be involved. The disease is related to smoking and alcohol use. Symptoms and complaints are based on the site involved and include hoarseness (when the larynx is involved) or dysphagia when the mouth, tonsils, or hypopharynx is involved. Patients may also present secondary to metastatic disease with a neck mass.

These tumors are grossly identical to conventional squamous cell carcinomas. Histologically, they are high grade and composed of mixtures of squamous cell carcinoma and adenocarcinoma. The squamous component usually predominates and can be either invasive or in situ. (5,166) The adenocarcinomatous component is always closely associated with the squamous elements, and it lacks the characteristic features of a distinctive form of salivary gland-type adenocarcinoma. Instead, it typically consists of moderately or poorly differentiated, "generic" adenocarcinoma, as evidenced by gland formation, usually with columnar-type cells or the production of intracellular mucin (Figure 7, A and B). (167) Typically, this component occurs in the deeper portions of the tumor. (166,167) Necrosis, mitotic figures, and perineural invasion are common.

The glandular elements of these tumors have been demonstrated to express carcinoembryonic antigen, low-molecular-weight cytokeratins, and CK7. (167,168) They are not reactive with antibodies to CK20. High-molecular-weight cytokeratins are present in both the squamous and glandular components. Overexpression of the p53 protein is seen in most cases. (22,167) Ten of 12 cases (83%) tested in one study (167) were aneuploid. MAML gene rearrangements, typically seen with mucoepidermoid carcinoma, are not seen with adenosquamous carcinomas. (169) Because some tumors may be associated with high-risk HPV infection, the molecular changes seen with those tumors (eg, intact p16 expression and overexpression) should be seen with some cases. (22)

In a review performed by Keelawat et al of upper aerodigestive tract adenosquamous carcinomas, 18.5% (5 of 27) of patients presented with stage 1 disease, 3.7% (1 of 27) with stage 2 disease, 25.9% (7 of 27) with stage 3 disease, and 51.9% (14 of 27) with stage 4. Forty-seven percent (21 of 45) of patients developed local recurrences; 65% (33 of 51) developed lymph node metastases, and 23% (12 of 52) developed distant metastases. The lung was the most common site involved by distant disease; however, other sites of reported involvement included the liver, bone, and kidney. (166)

BASALOID SQUAMOUS CELL CARCINOMA

The identification of HPV-associated squamous cell carcinomas, which often have a nonkeratinizing and somewhat basaloid morphology, has somewhat blurred the distinction with the basaloid squamous cell carcinoma variant. The morphologic overlap prompted studies of basaloid squamous cell carcinomas (BSCCs) to identify whether there was an HPV subset within this variant. Two recent studies (9,18) have demonstrated the presence of HPV 16 in a subset of BSCCs. Like most HPV-associated tumors, these HPV-associated BSCCs demonstrated an overall better prognosis and, not surprisingly, most were located in the oropharynx. As such, when a tumor meets the criteria for a BSCC, detection of HPV should be sought to identify this subset. As discussed above, the use of the term basaloid is being called into question when diagnosing HPV-related tumors and likely a new classification scheme will arise for segregating tumors of the head and neck based on their HPV status, with subtypes unique to both HPV and non-HPV groups. (17)

Basaloid squamous cell carcinoma was first described as a distinct entity in the head and neck region by Wain et al (170) in 1986. The clinical features of basaloid squamous cell carcinoma are generally similar to those of conventional squamous cell carcinoma. However, distinguishing features include a strong predilection to involve the base of the tongue, pyriform sinus, supraglottic larynx, and palatine tonsil and a tendency to present as advanced lesions. (170,171) There is a strong male predominance. The presenting complaints vary with anatomic site, but typically consist of sore throat, hoarseness, dysphagia, tinnitus, nasal obstruction, epistaxis, hemoptysis, and night sweats. (171)

The gross appearance of these tumors is not highly distinctive. However, it has been noted that basaloid squamous cell carcinomas are seldom exophytic, and they are often centrally ulcerated with considerable induration of the adjacent nonulcerated mucosa. (172,173) On cross-section, the tumors are typically dense, firm, pale, focally ulcerated, infiltrating masses. (172-174)

These tumors are composed of closely packed, moderately pleomorphic, basaloid cells arranged in variably sized nests and cords (Figure 8). Larger nests frequently exhibit central comedonecrosis. (170,171,173,174) In the smaller nests, single-cell necrosis. Cells at the edges of the nests may show nuclear palisading. A cribriform-like pattern within the cell nests from the interspersion of mucinous material or hyalinized stroma is common. Smaller glandlike spaces filled with mucin or hyalinized material may also been seen in the cell nests. The basaloid neoplastic cells have high nuclear to cytoplasmic ratios, often with dense, hyperchromatic nuclei. Occasionally, nuclei may be vesicular, with scattered nucleoli. Mitotic figures are usually numerous, and atypical forms are easily found. (171) Foci of overt squamous differentiation, consisting of cells with more abundant eosinophilic cytoplasm, intercellular bridges, or keratin pearl formation are invariably present. Occasionally, large zones of conventional squamous cell carcinoma may be found outside, but adjacent to, the basaloid component. (171) Rare cases of basaloid squamous cell carcinomas that have a spindle cell component have been reported. (175,176) An intact surface mucosa overlying a basaloid squamous cell carcinoma frequently demonstrates high-grade dysplasia. In such instances, the carcinoma appears to "drop off" from the overlying dysplastic epithelium.

Basaloid squamous cell carcinomas sometimes show surprisingly weak, focal, or absent reactivity for cytokeratins in the basaloid component. (171,177) Most examples will be reactive, at least focally, for cytokeratins, if one uses a cocktail. (171,177) The admixed components of conventional squamous cell carcinoma exhibit much stronger positivity. (171) Punctate cytokeratin positivity of the type encountered in small cell carcinomas is not seen. (171) Almost all basaloid squamous cell carcinomas show strong and diffuse immunoreactivity with antibodies to p63. (178-180) Tumors may display abortive neuroendocrine differentiation but are usually negative for synaptophysin and chromogra nin. (171,181,182) Myogenous antigens, such as smooth muscle actin, are usually not expressed (although there has been some reported variability) nor is CD117 (KIT). (171,181-183)

As expected in the HPV-associated subset, there is immunoreactivity with antibodies to p16. (9) In non-HPV-associated tumors, p53 overexpression has been found. (184,185) Choi et al (107) found head and neck basaloid squamous cell carcinomas to be more likely to show loss of heterozygosity at specific sites on chromosomes 9 and 11.

No approaches to treatment have been systematically studied that differ from those of conventional squamous cell carcinomas. Regardless of HPV tumor status, patients currently undergo resection, if possible, often followed by adjuvant radiation therapy, chemotherapy, or both. (171) Studies detailing the prognosis of these tumors report conflicting results, which will likely evolve as HPV-associated BSCCs are separated from non-HPV-associated BSCCs in follow-up data regarding survival and prognosis. (9,170,171,186-188)

PAPILLARY SQUAMOUS CELL CARCINOMA

Papillary squamous cell carcinoma is an uncommon variant of squamous cell carcinoma. It demonstrates a predilection for the larynx, oropharynx, and sinonasal tract and is more common in older men. (189-197) Symptoms are related to the site of involvement and the presence of invasive disease and metastases. Rarely, patients present with a prior history of noninvasive papillomas. However, the relationship of these neoplasms to benign papillary proliferations of the larynx and sinonasal region remains unclear. (189,190)

These tumors often have a grossly papillary appearance, similar to that of verrucous carcinoma, but they lack the prominent surface keratinization seen in the latter tumors. (190) Tumors are typically friable, soft, and varied from 0.2 to 4.0 cm in one larger study. (190) The noninvasive variant consists entirely of an exophytic proliferation of malignant-appearing squamous cells covering papillae with fibrovascular cores (Figure 9). (20,189-192,194) The epithelium varies in thickness. The epithelial cells are usually immature and basal cell-like, resembling squamous cell carcinoma in situ as described in the uterine cervix. Surface maturation and keratinization can be present but are typically limited. The invasive form of the tumor is similar to the noninvasive variant but contains an underlying component of invasive squamous cell carcinoma. The underlying invasive component may be keratinizing or nonkeratinizing. (189,190,20) Identifying or excluding the invasive component can be difficult when based on endoscopic biopsy specimens. Ancillary testing is not generally helpful for the diagnosis of papillary squamous cell carcinoma, and the diagnosis should rely on histologic criteria only.

Recent studies (20,107) have demonstrated HPV positivity in a subset of papillary squamous cell carcinomas. These HPV-related papillary squamous cell carcinomas are, not surprisingly, found in younger patients, display a nonkeratinizing morphology, and occur most often in the oropharynx. Given the rarity of these tumors, limited data are available on the prognosis of this HPV-associated papillary squamous cell carcinoma subtype; however, preliminary studies suggest improved disease-free survival. (20,198) Current treatment parallels that of conventional squamous cell carcinoma. Authors have suggested that these tumors be treated as potentially invasive until proven otherwise. (194)

NUCLEAR PROTEIN IN TESTIS MIDLINE CARCINOMA

Nuclear protein in testis (NUT) midline carcinoma (NMC) is an aggressive, rare variant of squamous cell carcinoma that is defined by its characteristic rearrangement of NUT on band 15q14. (199-203) The most common translocation involving the NUT gene is t(15;19)(q13;p13.1). (199-203) This translocation fuses the NUT gene on chromosome 15 to the BRD4 gene. However, other fusion partners, such as BRD3, have been described in about one-third of cases; these NMCs are given the designation NUT-variant tumors. (199,204) Implicit in its name, the term midline refers to its tendency to arise in the midline with the mediastinum and upper aerodigestive tract being its favored locations. (200) Initially thought to be a pediatric disease, NMCs are now recognized to have no gender or sex predilection. (200-202) Patients with NMCs frequently present with mass-related symptoms and non-specific symptoms, such as fever and weight loss have also been noted. (205-211)

The histologic features are that of a poorly differentiated carcinoma composed of monotonous, medium-sized, round cells with scant eosinophilic cytoplasm (Figure 10, A). (210,212-215) Nuclei have irregular contours with fine to vesicular chromatin and prominent nucleoli. Mitotic figures and apoptotic bodies are common. Occasional cases may have a more-nested pattern with a desmoplastic stromal response. Large areas of coagulative necrosis may be present. There is often focal abrupt keratinization with sheets of immature cells juxtaposed to well-differentiated, mature, often benign-appearing squamous nests. (201) A single case of the parotid gland has been described that additionally showed chondroid differentiation. (215)

This tumor is often misdiagnosed because it can be confused with a variety of poorly differentiated tumors. (202) Immunohistochemistry and ancillary studies, such as fluorescence in situ hybridization (FISH), cytogenetics, and RT-PCR can assist in the diagnosis. The NUT midline carcinomas are epithelial and react with antibodies to keratins (although staining may be focal). (212-214) Most of the tumors described are immunoreactive with antibodies to CK7 and sometimes show focal immunoreactivity with antibodies to CK20. (213) Most tumors express p63, consistent with squamous differentiation. CD34 expression was seen in a little more than one-half of the cases studied in one review. (213) Immunoreactivity with other antigens expressed in small blue cell tumors of childhood has not been noted. Evidence of EBV and HPV infection has not been identified, although p16 overexpression has been noted in some cases. (212)

The advent of the commercially available anti-NUT monoclonal antibody has now simplified its diagnosis. (216) The antibody demonstrates 87% sensitivity and 100% specificity. (216) A positive result is described as diffuse, speckled nuclear staining in more than 50% of tumor cells. (216) However, in cases where NMC is high on the differential, and IHC results for NUT are negative, further studies, such as FISH, are warranted to thoroughly exclude NMC (Figure 10, B). (216) The FISH probes have been developed for the regions flanking the typical breakpoint of the NUT gene on chromosome 15 and for the typical breakpoints with BRD4 and BRD3; however, they are not commercially available. As an alternative to FISH, RT-PCR primers have been developed for both fusion proteins; however RT-PCR remains less sensitive than FISH. (216)

The function of the NUT protein is not entirely known, although it is constitutively expressed in early germ cells and within the brain (ciliary ganglion). (199,212) Transcriptionally active chromatin is bound by the BRD proteins. (199,212) Fusion proteins are thought to be localized to the nucleus secondary to the expressed portions of the BRD4 and BRD3 proteins that are retained. (199) Further, the BRD-NUT fusion protein is thought to cause a block in differentiation via decreased expression of many genes through decreased histone acetylation. (199) This process is referred to as sequestration and details regarding this model can be found in a recent review (199) published in the journal Annual Review of Pathology.

The NMC tumors present at advanced stage and are often unresectable. (199,200) The treatment approach to NMC is heterogenous with a combination of surgery, multidrug chemotherapy, and radiation therapy. (199,200) Although the tumors initially respond to chemotherapy, they subsequently recur and become less responsive to treatment. (199,200) In the largest NMC study to date, Bauer et al (200) demonstrated that the median, overall survival was 6.7 months. Bauer et al (200) found intensive local therapy, such as total gross resection and radiotherapy, was associated with improved survival. However, no chemotherapeutic regimen emerged as having an improved outcome. (200) As the pathophysiology behind NMCs continues to unravel, new treatment options will likely become available. In vitro research is currently focused on developing small molecule inhibitors (eg, histone deacetylase inhibitors and BET inhibitors) with promising results. (199)

Please Note: Illustration(s) are not available due to copyright restrictions.

References

(1.) Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013;63(1):57-81.

(2.) Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012;6(suppl 1):S16-S24.

(3.) Gillison ML, Koch WM, Capone RB, et al. Evidenceforacausal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-720.

(4.) Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg. 1989;115(5):621-625.

(5.) El-Mofty SK. HPV-related squamous cell carcinoma variants in the head and neck. Head Neck Pathol. 2012;6(suppl 1):S55-S62.

(6.) Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer. 2004;108(5):766-772.

(7.) D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-1956.

(8.) El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2005;29(10):1367-1372.

(9.) Begum S, Westra WH. Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol. 2008;32(7):1044-1050.

(10.) BrandsmaJL, Steinberg BM, Abramson AL, Winkler B. Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. Cancer Res. 1986;46(4, pt 2):21 85-2188.

(11.) Bishop JA, Guo TW, Smith DF, et al. Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Path. 2013;37(2):185-192.

(12.) Goldenberg D, Begum S, Westra WH, et al. Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck. 2008;30(7):898-903.

(13.) Thompson LD, Heffner DK: The clinical importance of cystic squamous cell carcinomas in the neck: a study of 136 cases. Cancer. 1998;82(5):944-956.

(14.) Micheau C, Cachin Y, Caillou B. Cystic metastases in the neck revealing occult carcinoma of the tonsil: a report of six cases. Cancer. 1974;33(1):228-233.

(15.) Westra WH. The morphologic profile of HPV-related head and neck squamous carcinoma. Implications for diagnosis, prognosis and clinical management. Head Neck Pathol. 2012;6(suppl 1):S48-S54.

(16.) Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer: an association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997;79(3):595-604.

(17.) Chernock RD. Morphologic features of conventional squamous cell carcinoma of the oropharynx: 'keratinizing' and 'nonkeratinizing' histologic types as the basis for a consistent classification system. Head Neck Pathol. 2012; 6(suppl 1):S41-S47.

(18.) Chernock RD, Lewis JS Jr, Zhang Q, El-Mofty SK. Human papillomavirus positive basaloid squamous cell carcinoma of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Human Pathol. 2010;41(7):1016-1023.

(19.) Kleist B, Bankau A, Lorenz G, Jager B, Poetsch M. Different risk factors in basaloid and common squamous head and neck cancer. Laryngoscope. 2004; 114(6):1063-1068.

(20.) Jo VY, Mills SE, Stoler MH, Stelow EB. Papillary squamous cell carcinoma of the head and neck: frequent association with human papillomavirus infection and invasive carcinoma. Am J Surg Pathol. 2009;33(11):1720-1724.

(21.) Singhi AD, Stelow EB, Mills SE, Westra WH. Lymphoepithelial-like carcinoma of the oropharynx, a morphologic variant of HPV-related head and neck carcinoma. Am J Surg Pathol. 2010;34(6):800-805.

(22.) Masand RP, El-Mofty SK, Ma XJ, Luo Y, Flanagan JJ, Lewis JS Jr. Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol. 2011;5(2):1081-16.

(23.) Bishop JA, Westra WH. Human papillomavirus-related small cell carcinoma of the oropharynx. Am J Surg Pathol. 2011;35(11):1679-1684.

(24.) Venuti A, Paolini F. HPV detection methods in head and neck cancer. Head Neck Pathol. 2012;6(suppl 1):S63-S74.

(25.) Snijders PJ, Cromme FV, van den Brule AJ, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer. 1992;51(6):845-850.

(26.) Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol. 1998;152(1):145-115.

(27.) Ang KK, Sturgis EM. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012;22(2):128-142.

(28.) Weinberger PM, Yu Z, Haffty BG, etal. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736-747.

(29.) Sedaghat AR, Zhang Z, Begum S, et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope. 2009;119(8):1542-1549.

(30.) Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008, 100(4):261-269.

(31.) Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys. 2007;69(2):S109-S111.

(32.) Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128-3313.

(33.) Psyrri A, Sasaki C, Vassilakopoulou M, Dimitriadis G, Rampias T. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol. 2012;6(suppl 1):S121-S128.

(34.) Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22(33):5108-5121.

(35.) Barnes L, Eveson JW, Reichart PA, Sidransky D, eds. Pathology and Genetics of Head and Neck Tumors. Lyon, France: IARC Press; 2005:85-97. World Health Organization Classification of Tumours; vol 9.

(36.) Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995;146(6):1355-1367.

(37.) Nicholls JM, Agathanggelou A, Fung K, Zeng X, Niedobitek G. The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol. 1997;183(2):164-168.

(38.) Hildesheim A, Wang, CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 20002011: Rosetta stone for NPC: genetics, viral infection, and other environmental factors. Semin Cancer Biol. 2012;22(2):107-116.

(39.) Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22(2):79-86.

(40.) Creely JJ Jr, Lyons GD Jr, Trail ML. Cancer of the nasopharynx: a review of 114 cases. South Med J. 1973;66(4):405-409.

(41.) Easton JM, Levine PH, Hyams VJ. Nasopharyngeal carcinoma in the United States: a pathologic study of 177 US and 30 foreign cases. Arch Otolaryngol. 1980;106(2):88-91.

(42.) Shanmugaratnam K, Chan SH, de-The G, et al. Histopathology of nasopharyngeal carcinoma: correlations with epidemiology, survival rates and other biological characteristics. Cancer. 1979;44(3):1029-1044.

(43.) Bloom SM. Cancer of the nasopharynx: a study of ninety cases. J Mt Sinai Hosp N Y. 1969;36(4):277-298.

(44.) Giffler RF, Gillespie JJ, Ayala AG, Newland JR. Lymphoepithelioma in cervical lymph nodes of children and young adults. Am J Surg Pathol. 1977;1: 293-302.

(45.) Leighton SE, Teo JG, Leung SF, Cheung AY, Lee JC, van Hasselt CA. Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. Cancer. 1996;77(3):436-440.

(46.) Looi LM. Tumor-associated tissue eosinophilia in nasopharyngeal carcinoma: a pathologic study of 422 primary and 138 metastatic tumors. Cancer. 1987;59(3):466-470.

(47.) Regaud C, Reverchon L. Sur un cas d' epithelioma epidermoide developpe dans le massif maxillaire superieure etendu aux ligaments de la face, aux cavites buccale, nasale et orbitaire ainsi qu'aux ganglions du cou gueri par la radiotherapie. Rev Laryngol Otol Rhinol (Bord). 1921;42:369-378.

(48.) Schmincke A. Uber lympho-epitheliale geschwulste. Beitr Pathol Anat Allg Pathol. 1921;68:161-170.

(49.) Carbone A, Micheau C. Pitfalls in microscopic diagnosis of undifferentiated carcinoma of nasopharyngeal type (lymphoepithelioma). Cancer. 1982; 50(7):1344-1351.

(50.) Zarate-Osorno A, Jaffe ES, Medeiros LJ. Metastatic nasopharyngeal carcinoma initially presenting as cervical lymphadenopathy: a report of two cases that resembled Hodgkin's disease. Arch Pathol Lab Med. 1992;116(8):862-865.

(51.) Kamino H, Huang SJ, Fu YS. Keratin and involucrin immunohistochemistry of nasopharyngeal carcinoma. Cancer. 1988;61(6):1142-1148.

(52.) Kurtin PJ, Pinkus GS. Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization. Hum Pathol 1985;16(4):353-365.

(53.) Lauder I, Holland D, Mason DY, Gowland G, CunliffeWJ. Identification of large cell undifferentiated tumours in lymph nodes using leucocyte common and keratin antibodies. Histopathology. 1984;8(2):259-272.

(54.) Madri JA, Barwick KW. An immunohistochemical study of nasopharyngeal neoplasms using keratin antibodies: epithelial versus nonepithelial neoplasms. Am J Surg Pathol. 1982; 6(2):143-149.

(55.) Pinkus GS, Kurtin PJ. Epithelial membrane antigen--a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol. 1985;16(9):929-940.

(56.) Shi SR, Goodman ML, Bhan AK, Pilch BZ, Chen LB, Sun TT. Immunohistochemical study of nasopharyngeal carcinoma using monoclonal keratin antibodies. Am J Pathol. 1984;117(1):53-63.

(57.) Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology. Cancer. 1981;47(7):1786-1795.

(58.) TaxyJB, Hidvegi DF, Battifora H. Nasopharyngeal carcinoma: antikeratin immunohistochemistry and electron microscopy. Am J Clin Pathol. 1985;83(3): 320-325.

(59.) Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies.N Engl J Med. 1983;309(21):1275-1281.

(60.) Ziegels-Weissman J, Nadji M, Penneys NS, Morales AR. Prekeratin immunohistochemistry in the diagnosis of undifferentiated carcinoma of the nasopharyngeal type. Arch Pathol Lab Med. 1984;108(7):588-589.

(61.) Bourne TD, Bellizzi AM, Stelow EB, et al. p63 expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract. Am J Clin Pathol. 2008;130(2):213-218.

(62.) Chao TY, Chow KC, Chang JY, et al. Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma. Cancer. 1996;78(1):24-29.

(63.) Iezzoni JC, Gaffey MJ, Weiss LM. The role of Epstein-Barr virus in lymphoepithelioma-like carcinomas. Am J Clin Pathol. 1995;103(3):308-315.

(64.) Hsiao JR, Jin YT, Tsai ST. EBER1 in situ hybridization as an adjuvant for diagnosis of recurrent nasopharyngeal carcinoma. Anticancer Res. 1998;18(6B): 4585-4589.

(65.) Hwang TZ, Jin YT, Tsai ST. EBER in situ hybridization differentiates carcinomas originating from the sinonasal region and the nasopharynx. Anticancer Res. 1998;18(6B):4581-4584.

(66.) Tsai ST, Jin YT, Mann RB, Ambinder RF. Epstein-Barr virus detection in nasopharyngeal tissues of patients with suspected nasopharyngeal carcinoma. Cancer. 1998;82(8):1449-1453.

(67.) Plaza G, Manzanal AI, Fogue L, Santon A, Martinez-Montero JC, Bellas C. Association of Epstein-Barr virus and nasopharyngeal carcinoma in Caucasian patients. Ann Otol Rhinol Laryngol. 2002;111 (3):210-216.

(68.) Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.Clin Cancer Res. 200;8(1):131-137.

(69.) Lo KW, Mok CH, Huang DP, et al. p53 mutation in human nasopharyngeal carcinomas, Anticancer Res. 1992;12(6B):1957-1963.

(70.) Sun Y, Hegamyer G, Colburn NH. Nasopharyngeal carcinoma shows no detectable retinoblastoma susceptibility gene alterations. Oncogene. 1993;8(3): 791-795.

(71.) Chien G, Yuen PW, Kwong D, Kwong YL. Comparative genomic hybridization analysis of nasopharyngeal carcinoma: consistent patterns of genetic aberrations and clinicopathological correlations. Cancer Genet Cytogenet. 2001;126(1):63-67.

(72.) Fang Y, Guan X, Guo Y, et al. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer. 2001;30(3):254-260.

(73.) Spratt DE, Lee N. Current and emerging treatment options for nasopharyngeal carcinoma. Onco Targets Ther. 2012;5:297-308. doi:10.2147/ OTT.S28032.

(74.) Rottey S, Madani I, Deron P, Van Belle S. Modern treatment for nasopharyngeal carcinoma: current status and prospects. Curr Opin Oncol. 2011;23(3):254-258.

(75.) Fridell HL, Rosenthal LN. The etiologic role of chewing tobacco in cancer of the mouth: report of eight cases treated with radiation. JAMA. 1941;116(19): 2130-2135.

(76.) Ackerman LV. Verrucous carcinoma of the oral cavity. Surgery. 1948; 23(4):670-678.

(77.) Ferlito A, Recher G. Ackerman's tumor (verrucous carcinoma) of the larynx: a clinicopathologic study of 77 cases. Cancer. 1980;46(7):1617-1630.

(78.) Lundgren JA, van Nostrand AW, Harwood AR, Cullen RJ, Bryce DP. Verrucous carcinoma (Ackerman's tumor) of the larynx: diagnostic and therapeutic considerations. Head Neck Surg. 1986;9(1):19-26.

(79.) Rajendran R, Varghese I, Sugathan CK, Vijayakumar T. Ackerman's tumour (verrucous carcinoma) of the oral cavity: a clinico-epidemiologic study of 426 cases. Aust Dent J. 1988;33(4):295-298.

(80.) Walvekar RR, Chaukar DA, Deshpande MS, et al. Verrucous carcinoma of the oral cavity: a clinical and pathological study of 101 cases. Oral Oncol. 2009; 45(1):47-51.

(81.) Abramson AL, BrandsmaJ, Steinberg B, Winkler B. Verrucous carcinoma of the larynx: possible human papillomavirus etiology. Arch Otolaryngol. 1985; 111(11):709-715.

(82.) Hagen P, Lyons GD, Haindel C. Verrucous carcinoma of the larynx: role of human papillomavirus, radiation, and surgery. Laryngoscope. 1993;103(3): 253-257.

(83.) Shroyer KR, Greer RO, Fankhouser CA, McGuirt WF, Marshall R. Detection of human papillomavirus DNA in oral verrucous carcinoma by polymerase chain reaction. Mod Pathol. 1993;6(6):669-672.

(84.) Nunez DA, Astley SM, Lewis FA, Wells M. Human papilloma viruses: a study of their prevalence in the normal larynx. J Laryngol Otol. 1994;8(4):319-320.

(85.) Orvidas LJ, Lewis JE, Olsen KD, Weiner JS. Intranasal verrucous carcinoma: relationship to inverting papilloma and human papillomavirus. Laryngoscope. 1999;109(3):371-375.

(86.) Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(6):622-635.

(87.) Luo CW, Roan CH, Liu CJ. Human papillomaviruses in oral squamous cell carcinoma and pre-cancerous lesions detected by PCR-based gene-chip array. Int J Oral Maxillofac Surg. 2007;36(2):153-158.

(88.) Fliss DM, Noble-Topham SE, McLachlin M, et al. Laryngeal verrucous carcinoma: a clinicopathologic study and detection of human papillomavirus using polymerase chain reaction. Laryngoscope. 1994;104(2):146-152.

(89.) Jin YT, Toto PD. Detection of human papovavirus antigen in oral papillary lesions. Oral Surg Oral Med Oral Pathol. 1984;58(6):702-705.

(90.) Young SK, Min KW. In situ DNA hybridization analysis of oral papillomas, leukoplakias, and carcinomas for human papillomavirus. Oral Surg Oral Med OralPathol. 1991;71(6):726-729.

(91.) Fonts EA, Greenlaw RH, Rush BF, Rovin S. Verrucous squamous cell carcinoma of the oral cavity. Cancer. 1969;23(1):152-160.

(92.) Kraus FT, Perezmesa C. Verrucous carcinoma: clinical and pathologic study of 105 cases involving oral cavity, larynx, and genitalia. Cancer. 1966; 19(1):26-38.

(93.) McCoy JM, Waldron CA. Verrucous carcinoma of the oral cavity: a review of forty-nine cases. Oral Surg Oral Med Oral Pathol. 1981;52(6):623-629.

(94.) Medina JE, Dichtel W, Luna MA. Verrucous-squamous carcinomas of the oral cavity: s clinicopathologic study of 104 cases. Arch Otolaryngol. 1984; 110(7):437-440.

(95.) Orvidas LJ, Olsen KD, Lewis JE, Suman VJ. Verrucous carcinoma of the larynx: a review of 53 patients. Head Neck. 1998;20(3):197-203.

(96.) Ryan RE Jr, DeSanto LW, Devine KD, Weiland LH. Verrucous carcinoma of the larynx. Laryngoscope. 1977;87(12):1989-1994.

(97.) Batsakis JG, Hybels R, Crissman JD, Rice DH. The pathology of head and neck tumors: verrucous carcinoma. Head Neck Surg. 1982;5(1):29-38.

(98.) Cooke RA. Verrucous carcinoma of the oral mucosa in Papua-New Guinea. Cancer. 1969;24(2):397-402.

(99.) Edstrom S, Johansson SL, Lindstrom J, Sandin I. Verrucous squamous cell carcinoma of the larynx: evidence for increased metastatic potential after irradiation. Otolaryngol Head Neck Surg. 1987;97(4):381-384.

(100.) Ferlito A, Antonutto G, Silvestri F. Histological appearances and nuclear DNA content of verrucous squamous cell carcinoma of the larynx. ORL J Otorhinolaryngol Relat Spec. 1976;38(2):65-68.

(101.) Kahn JL, Blez P, Gasser B, Weill-Bousson M, Vetter JM, Champy M. Carcinoma cuniculatum: apropos of 4 cases with orofacial involvement. Rev Stomatol Chir Maxillofac. 1991;92(1):27-33.

(102.) Eversole LR, Papanicolaou SJ. Papillary and verrucous lesions of oral mucous membranes. J Oral Med. 1983;38(1):3-13.

(103.) Prioleau PG, Santa Cruz DJ, Meyer JS, Bauer WC. Verrucous carcinoma: a light and electron microscopic, autoradiographic, and immunofluorescence study. Cancer. 1980;45(11):2849-2857.

(104.) Youngberg GA, Thornthwaite JT, Inoshita T, Franzus D. Cytologically malignant squamous-cell carcinoma arising in a verrucous carcinoma of the penis. J Dermatol Surg Oncol. 1983;9(6):474-479.

(105.) Sakurai K, Urade M, Takahashi Y, et al. Increased expression of c-erbB-3 protein and proliferating cell nuclear antigen during development of verrucous carcinoma of the oral mucosa. Cancer. 2000;89(12):2597-2605.

(106.) Maraki D, Boecking A, Pomjanski N, Megahed M, Becker J. Verrucous carcinoma of the buccal mucosa: histopathological, cytological and DNA-cytometric features. J Oral Pathol Med. 2006;35(10):633-635.

(107.) Choi HR, Roberts DB, Johnigan RH, et al. Molecular and clinicopathologic comparisons of head and neck squamous carcinoma variants: common and distinctive features of biological significance. Am J Surg Pathol. 2004;28(10): 1299-1310.

(108.) Poh CF, Zhang L, Lam WL, et al. A high frequency of allelic loss in oral verrucous lesions may explain malignant risk. Lab Invest. 2001;81(4):629-634.

(109.) Anderson JA, Irish JC, McLachlin CM, Ngan BY. H-ras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch Otolaryngol Head Neck Surg. 1994;120(7):755-760.

(110.) Lessard JL, Robinson RA, Hoffman HT. Differential expression of ras signal transduction mediators in verrucous and squamous cell carcinomas of the upper aerodigestive tract. Arch Pathol Lab Med. 2001;125(9):1200-1203.

(111.) Gimenez-Conti IB, Collet AM, Lanfranchi H, et al. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer. 1996;78(1):17-23.

(112.) Lopez-Amado M, Garcia-Caballero T, Lozano-Ramirez A, Labella-Caballero T. Human papillomavirus and p53 oncoprotein in verrucous carcinoma of the larynx. J Laryngol Otol. 1996;110(8):742-747.

(113.) Angadi PV, Krishnapillai R. Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma: correlation with histological differentiation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(3):e30-e35.

(114.) Lin HP, Wang YP, Chiang CP. Expression of p53, MDM2, p21, heat shock protein 70, and HPV 16/18 E6 proteins in oral verrucous carcinoma and oral verrucous hyperplasia. Head Neck. 2011;33(3):334-340.

(115.) Kato K, Hara A, Kuno T, et al. Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res Clin Oncol. 2006;132(11):735-743.

(116.) Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C. Aberrant [beta]-catenin expression in the histologic differentiation of oral squamous cell carcinoma and verrucous carcinoma: an immunohistochemical study. J Oral Sci. 2010;52(4): 633-640.

(117.) Tharp ME II, Shidnia H. Radiotherapy in the treatment of verrucous carcinoma of the head and neck. Laryngoscope. 1995;105(4):391-396.

(118.) Huang SH, Lockwood G, Irish J, et al. Truths and myths about radiotherapy for verrucous carcinoma of larynx. Int J Radiat Oncol Biol Phys. 2009;73(4):1110-111 5.

(119.) Strojan P, Smid L, Cizmarevic B, Zagar T, Auersperg M: Verrucous carcinoma of the larynx: determining the best treatment option. Eur J Surg Oncol. 2006;32(9):984-988.

(120.) Wu CF, Chen CM, Shen YS, et al. Effective eradication of oral verrucous carcinoma with continuous intraarterial infusion chemotherapy. Head Neck. 2008;30(5):611-617.

(121.) Strojan P, Soba E, Budihna M, Auersperg M. Radiochemotherapy with vinblastine, methotrexate, and bleomycin in the treatment of verrucous carcinoma of the head and neck. J Surg Oncol. 2005;92(4):278-283.

(122.) Chen HM, Chen CT, Yang H, et al. Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy. J Oral Pathol Med. 2005;34(4):253-256.

(123.) Leventon GS, Evans HL. Sarcomatoid squamous cell carcinoma of the mucous membranes of the head and neck: a clinicopathologic study of 20 cases. Cancer. 1981;48(4):994-1003.

(124.) Weidner N. Sarcomatoid carcinoma of the upper aerodigestive tract. Semin Diagn Pathol. 1987;4(2):157-168.

(125.) Lasser KH, Cove H, Naeim F, Waisman J, Higgins J. "Pseudosarcoma" of the larynx. Am J Surg Pathol. 1979;3(5):397-404.

(126.) Thompson LD, Wieneke JA, Miettinen M, Heffner DK. Spindle cell (sarcomatoid) carcinomas of the larynx: a clinicopathologic study of 187 cases. Am J Surg Pathol. 2002;26(2):153-170.

(127.) Alguacil-Garcia A, Alonso A, Pettigrew NM. Sarcomatoid carcinoma (so-called pseudosarcoma) of the larynx simulating malignant giant cell tumor of soft parts: a case report. Am J Clin Pathol. 1984;82(3):340-343.

(128.) Battifora H. Spindle cell carcinoma ultrastructural evidence of squamous origin and collagen production by the tumor cells. Cancer. 1976;37(5):2275-2282.

(129.) Benninger MS, Kraus D, Sebek B, Tucker HM, Lavertu P. Head and neck spindle cell carcinoma: an evaluation of current management. Cleve Clin J Med. 1992;59(5):479-482.

(130.) Berthelet E, Shenouda G, Black MJ, Picariello M, Rochon L. Sarcomatoid carcinoma of the head and neck. Am J Surg. 1994;168(5):455-458.

(131.) Ellis GL, LanglossJM, Heffner DK, Hyams VJ. Spindle-cell carcinoma of the aerodigestive tract: an immunohistochemical analysis of 21 cases. Am J Surg Pathol. 1987;11(5):335-342.

(132.) Howell JH, Hyams VJ, Sprinkle PM. Spindle cell carcinoma of the nose and paranasal sinuses. Surg Forum. 1978;29:565-568.

(133.) Hyams VJ. Spindle cell carcinoma of the larynx. Can J Otolaryngol. 1975; 4(2):307-313.

(134.) Lambert PR, Ward PH, Berci G. Pseudosarcoma of the larynx: a comprehensive analysis. Arch Otolaryngol. 1980;106(11):700-708.

(135.) Lichtiger B, Mackay B, Tessmer CF. Spindle-cell variant of squamous carcinoma: a light and electron microscopic study of 13 cases. Cancer. 1970; 26(6):1311-1320.

(136.) Piscioli F, Aldovini D, Bondi A, Eusebi V. Squamous cell carcinoma with sarcoma-like stroma of the nose and paranasal sinuses: report of two cases. Histopathology. 1984;8(4):633-639.

(137.) Zarbo RJ, Crissman JD, Venkat H, Weiss MA. Spindle-cell carcinoma of the upper aerodigestive tract mucosa: an immunohistologic and ultrastructural study of 18 biphasic tumors and comparison with seven monophasic spindle-cell tumors. Am J Surg Pathol. 1986;10(11):741-753.

(138.) Lewis JE, Olsen KD, Sebo TJ. Spindle cell carcinoma of the larynx: review of 26 cases including DNA content and immunohistochemistry. Hum Pathol. 1997;28(6):664-673.

(139.) Batsakis JG, Suarez P. Sarcomatoid carcinomas of the upper aerodigestive tracts. Adv Anat Pathol. 2000;7(5):282-293.

(140.) Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder--p63, MOC31, and TTF-1. ModPathol. 2005;18(11):1471-1481.

(141.) Viswanathan S, Rahman K, Pallavi S, et al. Sarcomatoid (spindle cell) carcinoma of the head and neck mucosal region: a clinicopathologic review of 103 cases form a tertiary referral cancer centre. Head Neck Pathol. 2010;4(4): 265-275.

(142.) Ansari-Lari MA, Hoque MO, CalifanoJ, Westra WH. Immunohistochemical p53 expression patterns in sarcomatoid carcinomas of the upper respiratory tract. Am J Surg Pathol. 2002;26(8):1024-1031.

(143.) Romanach MJ, Azevedo RS, Carlos R, de Almeida OP, Pires FR. Clinicopathological and immunohistochemical features of oral spindle cell carcinoma. J Oral Pathol Med 2010;39(4):335-341.

(144.) Olsen KD, Lewis JE, Suman VJ. Spindle cell carcinoma of the larynx and hypopharynx. Otolaryngol Head Neck Surg. 1997;116(1):47-52.

(145.) Torenbeek R, Hermsen MA, Meijer GA, BaakJP, Meijer CJ. Analysis by comparative genomic hybridization of epithelial and spindle cell components in sarcomatoid carcinoma and carcinosarcoma: histogenetic aspects. J Pathol. 1999; 189(3):338-343.

(146.) Choi HR, Sturgis EM, Rosenthal DI, LunaMA, BatsakisJG, El-NaggarAK. Sarcomatoid carcinoma of the head and neck: molecular evidence for evolution and progression from conventional squamous cell carcinomas. Am J Surg Pathol. 2003;27(9):1216-1220.

(147.) Nguyen PT, Kudo Y, Yoshida M, lizuka S, Ogawa I, Takata T. N-cadherin expression is correlated with metastasis of spindle cell carcinoma of head and neck region. J Oral Pathol Med. 2011;40(1):77-82.

(148.) Johnson WC, Helwig EB. Adenoid squamous cell carcinoma (adenoacanthoma): a clinicopathologic study of 155 patients. Cancer. 1966;19(11):1639-1650.

(149.) Lever WF. Adenoacanthoma of sweat glands: carcinoma of sweat glands with glandular and epidermal elements. Arch Dermatol Syphilol. 1947;56(2): 157-171.

(150.) Nappi O, Wick MR, Pettinato G, Ghiselli RW, Swanson PE. Pseudovascular adenoid squamous cell carcinoma of the skin: a neoplasm that may be mistaken for angiosarcoma. Am J Surg Pathol. 1992;16(5):429-438.

(151.) Goldman RL, Klein HZ, Sung M. Adenoid squamous cell carcinoma of the oral cavity: report of the first case arising in the tongue. Arch Otolaryngol. 1977;103(8):496-498.

(152.) Jacoway JR, Nelson JF, Boyers RC. Adenoid squamous-cell carcinoma (adenocanthoma) of the oral labial mucosa: a clinicopathologic study of fifteen cases. Oral Surg Oral Med Oral Pathol. 1971;32(3):444-449.

(153.) Takagi M, Sakota Y, Takayama S, Ishikawa G. Adenoid squamous cell carcinoma of the oral mucosa: report of two autopsy cases. Cancer. 1977;40(5): 2250-2255.

(154.) Weitzner S. Adenoid squamous-cell carcinoma of vermilion mucosa of lower lip. Oral Surg Oral Med Oral Pathol. 1974;37(4):589-59.

(155.) Zaatari GS, Santoianni RA. Adenoid squamous cell carcinoma of the nasopharynx and neck region. Arch Pathol Lab Med. 1986;110(6):542-546.

(156.) Batsakis JG, Huser J. Squamous carcinomas with glandlike (adenoid) features. Ann Otol Rhinol Laryngol. 1990;99(1):87-88.

(157.) Ferlito A, Devaney KO, Rinaldo A, Milroy CM, Carbone A. Mucosal adenoid squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1996;105(5):409-413.

(158.) Hertenstein JC. Pathologic quiz case 1: acantholytic squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1986;112(7):780-782.

(159.) Gonzalez-Vela MC, Val-Bernal JF, Mayorga M, Zaldumbide L, Bascones M. Adenoid squamous cell carcinoma of the larynx: an uncommon histological variant of squamous cell carcinoma. APMIS. 2006;114(6):470-473.

(160.) Kerawala CJ. Acantholytic squamous cell carcinoma of the oral cavity: a more aggressive entity? Br J Oral Maxillofac Surg. 2009;47(2):123-125.

(161.) Papadopoulou E, Tosios KI, Nikitakis N, Papadogeorgakis N, Sklavousnous-Andrikopoulou A. Acantholytic squamous cell carcinoma of the gingival: report of a case and review of the literature. Oral Surg Oral Med Oral Path Oral Radiol Endod. 2010;109(6):e67-e71.

(162.) Jones AC, Freedman PD, Kerpel SM. Oral adenoid squamous cell carcinoma: a report of three cases and review of the literature. J Oral Maxillofac Surg. 1993;51(6):676-681.

(163.) Nappi O, Swanson PE, Wick MR. Pseudovascular adenoid squamous cell carcinoma of the lung: clinicopathologic study of three cases and comparison with true pleuropulmonary angiosarcoma. Hum Pathol. 1994;25(4):373-378.

(164.) Napier SS, Gormely JS, Newlands C, Ramsay-Baggs P. Adenosquamous carcinoma: a rare neoplasm with an aggressive course. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79(5):607-611.

(165.) Tadashi Terada. Adenoid squamous cell carcinoma of the oral cavity. Int J Clin Exp Pathol. 2012;5(5):442-447.

(166.) Keelawat S, Liu CZ, Roehm PC, Barnes L. Adenosquamous carcinoma of the upper aerodigestive tract: a clinicopathologic study of 12 cases and review of the literature. Am J Otolaryngol. 2002;23(3):160-168.

(167.) Alos L, Castillo M, Nadal A, et al. Adenosquamous carcinoma of the head and neck: criteria for diagnosis in a study of 12 cases. Histopathology. 2004; 44(6):570-579.

(168.) Martinez-Madrigal F, Baden E, Casiraghi O, Micheau C. Oral and pharyngeal adenosquamous carcinoma: a report of four cases with immunohistochemical studies. Eur Arch Otorhinolaryngol. 1991;248(5):255-258.

(169.) Seethala RR, Zhang X, Turner S, et al. Adenosquamous carcinomas of the head and neck: an analysis of MDM2, p53 expression and MAML2 rearrangements [Abstract 1143]. Mod Pathol. 2009;22(1):251A.

(170.) Wain SL, Kier R, Vollmer RT, Bossen EH. Basaloid-squamous carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. Hum Pathol. 1986; 17(11):1158-1166.

(171.) Banks ER, Frierson HF Jr, Mills SE, George E, Zarbo RJ, Swanson PE. Basaloid squamous cell carcinoma of the head and neck: a clinicopathologic and immunohistochemical study of 40 cases. Am J Surg Pathol. 1992;16(10):939-946.

(172.) Ereno C, Lopez JI, Sanchez JM, Toledo JD. Basaloid-squamous cell carcinoma of the larynx and hypopharynx: a clinicopathologic study of 7 cases. Pathol Res Pract. 1994;190(2):186-193.

(173.) Luna MA, el Naggar A, Parichatikanond P, Weber RS, Batsakis JG. Basaloid squamous carcinoma of the upper aerodigestive tract: clinicopathologic and DNA flow cytometric analysis. Cancer. 1990;66(3):537-542.

(174.) Raslan WF, Barnes L, Krause JR, Contis L, Killeen R, KapadiaSB. Basaloid squamous cell carcinoma of the head and neck: a clinicopathologic and flow cytometric study of 10 new cases with review of the English literature. Am J Otolaryngol. 1994;15(3):204-211.

(175.) Altrabulsi B, Carrizo F, Luna MA. Spindle basaloid squamous carcinoma of the upper aerodigestive tract: immunohistochemical and clinicopathological study of three cases. Ann Diagn Pathol. 2006;10(3):149-153.

(176.) Kimura T, Mukai M, Shiotani A, Moro K, Ikeda A, Okada Y. Basaloid squamous carcinoma of the hypopharynx with an extensive spindle cell component exhibiting a pedunculated polypoid mass. Arch Pathol Lab Med. 2005;129(4):e94-96.

(177.) Tsang WY, Chan JK, Lee KC, Leung AK, Fu YT. Basaloid-squamous carcinoma of the upper aerodigestive tract and so-called adenoid cystic carcinoma of the oesophagus: the same tumour type? Histopathology. 1991; 19(1):35-46.

(178.) Chapman-Fredricks J, Jorda M, Gomez-Fernandez C. A limited immunohistochemical panel helps differentiate small cell epithelial malignancies of the sinonasal cavity and nasopharynx. Appl Immunohistochem. Mol Morphol. 2009; 17(3):207-210.

(179.) Emanuel P, Wang B, Wu M, Burstein DE. p63 immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol. 2005;18(5):645-650.

(180.) Serrano MF, El-Mofty SK, Gnepp DR, Lewis JS Jr. Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol. 2008;39(4):591-598.

(181.) Wieneke JA, Thompson LD, Wenig BM. Basaloid squamous cell carcinoma of the sinonasal tract. Cancer. 1999;85(4):841-854.

(182.) Morice WG, Ferreiro JA. Distinction of basaloid squamous cell carcinoma from adenoid cystic and small cell undifferentiated carcinoma by immunohistochemistry. Hum Pathol 1998;29(6):609-612.

(183.) Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol. 2003;16(12):1224-1231.

(184.) Yu GY, Gao Y, Peng X, Chen Y, Zhao FY, Wu MJ. A clinicopathologic study on basaloid squamous cell carcinoma in the oral and maxillofacial region. Int J Oral Maxillofac Surg. 2008;37(11):1003-1008.

(185.) Ferlito A, Altavilla G, Rinaldo A, Doglioni C. Basaloid squamous cell carcinoma of the larynx and hypopharynx. Ann Otol Rhinol Laryngol. 1997; 106(12):1024-1035.

(186.) Paulino AF, Singh B, Shah JP, Huvos AG. Basaloid squamous cell carcinoma of the head and neck. Laryngoscope. 2000;110(9):1479-1482.

(187.) de Sampaio Goes FC, Oliveira DT, Dorta RG, Nishimoto IN, Landman G, Kowalski LP. Prognoses of oral basaloid squamous cell carcinoma and squamous cell carcinoma: a comparison. Arch Otolaryngol Head Neck Surg. 2004;130(1): 83-86.

(188.) Zbaren P, Nuyens M, Stauffer E. Basaloid squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2004;12(2):116-121.

(189.) Batsakis JG, Suarez P. Papillary squamous carcinoma: will the real one please stand up? Adv Anat Pathol. 2000;7(1):2-8.

(190.) Suarez PA, Adler-Storthz K, Luna MA, El-Naggar AK, Abdul-Karim FW, Batsakis JG. Papillary squamous cell carcinomas of the upper aerodigestive tract: a clinicopathologic and molecular study. Head Neck. 2000;22(4):360-368.

(191.) Cobo F, Talavera P, Concha A. Review article: relationship of human papillomavirus with papillary squamous cell carcinoma of the upper aerodigestive tract: a review. Int J Surg Pathol. 2008;16(2):127-136.

(192.) Crissman JD, Kessis T, Shah KV, Fu YS, Stoler MH, Zarbo RJ, Weiss MA. Squamous papillary neoplasia of the adult upper aerodigestive tract. Hum Pathol. 1988;19(12):1387-1396.

(193.) Judd R, Zaki SR, Coffield LM, Evatt BL. Human papillomavirus type 6 detected by the polymerase chain reaction in invasive sinonasal papillary squamous cell carcinoma. Arch Pathol Lab Med. 1991;115(11):1150-1153.

(194.) Thompson LD, Wenig BM, Heffner DK, Gnepp DR. Exophytic and papillary squamous cell carcinomas of the larynx: a clinicopathologic series of 104 cases. Otolaryngol Head Neck Surg. 1999;120(5):718-724.

(195.) Ereno C, Lopez JI, Sanchez JM, Bilbao FJ. Papillary squamous cell carcinoma of the larynx. J Laryngol Otol. 2001;115(2):164-166.

(196.) Ferrer MJ, Estelles E, Villanueva A, Lopez R. Papillary squamous cell carcinoma of the oropharynx. Eur Arch Otorhinolaryngol. 2003;60(8):444-445.

(197.) Friedberg SA, Stagman R, Hass GM: Papillary lesions of the larynx in adults: a pathologic study. Ann Otol Rhinol Laryngol. 1971;80(5):683-692.

(198.) Mehrad M, Carpenter DH, Chernock RD, et al. Characterization of the head and neck papillary squamous cell carcinoma variants: clinicopathologic and molecular study with special reference to human papillomavirus (HPV) association [Abstract 1315]. Mod Pathol. 2012;25(suppl 2):313A. doi:10.1038/ modpathol.2012.20.

(199.) French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol Mech Dis. 2012;7:247-65.

(200.) Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18(20): 5773-5779.

(201.) Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008;32(6):828-834.

(202.) Davis BN, Karabakhtsian RG, Pettigrew AL, Arnold SM, French CA, Brill YM. Nuclear protein in testis midline carcinomas: a lethal and under-recognized entity. Arch Pathol Lab Med. 2011;135(11):1494-1498.

(203.) Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol. 2012;36(8):1216-1221.

(204.) French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27(15):2237-2242.

(205.) Kubonishi I, Takehara N, Iwata J, et al. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res. 1991;51(12): 3327-3328.

(206.) Engleson J, Soller M, Panagopoulos I, Dahlen A, Dictor M, Jerkeman M. Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-yearold female with response to docetaxel and radiotherapy. BMC Cancer. 2006;6(3): 69. doi:10.1186/1471-2407-6-69.

(207.) Lee AC, Kwong YI, Fu KH, Chan GC, Ma L, Lau YL. Disseminated mediastinal carcinoma with chromosomal translocation (15;19): a distinctive clinicopathologic syndrome. Cancer. 1993;72(7):2273-2276.

(208.) Mertens F, Wiebe T, Adlercreutz C, Mandahl N, French CA. Successful treatment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer. 2007;49(7):1015-1017.

(209.) Toretsky JA, Jenson J, Sun CC, et al. Translocation (11;15;19): a highly specific chromosome rearrangement associated with poorly differentiated thymic carcinoma in young patients. Am J Clin Oncol. 2003;26(3):300-306.

(210.) Vargas SO, French CA, Faul PN, et al. Upper respiratory tract carcinoma with chromosomal translocation 15;19: evidence for a distinct disease entity of young patients with a rapidly fatal course. Cancer. 2001;92(5):1195-1203.

(211.) Hsieh MS, French CA, Liang CW, Hsiao CH. NUT midline carcinoma: case report and review of the literature. Int J Surg Pathol. 2011;19(6):808-812.

(212.) French CA. Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol. 2010;63(6):492-496.

(213.) French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004;22(20):4135-4139.

(214.) Stelow EB, Mills SE. Squamous cell carcinoma variants of the upper aerodigestive tract. Am J Clin Pathol. 2005;214:S96-109.

(215.) den Bakker MA, Beverloo BH, van den Heuvel-Eibrink MM, et al. NUT midline carcinoma of the parotid gland with mesenchymal differentiation. Am J Surg Pathol. 2009;33(8):1253-1258.

(216.) Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009(7);33:984-991.

Akeesha A. Shah, MD; Susanne K. Jeffus, MD; Edward B. Stelow, MD

Accepted for publication May 20, 2013.

From the Department of Pathology, University of Virginia Health System, Charlottesville.

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Edward B. Stelow, MD, Department of Pathology, University of Virginia Health System, Box 8002, Jefferson Park Ave, Charlottesville, VA 22908 (e-mail: edstelow@yahoo.com).

* References 10, 76-83, 92, 93, 95-101.

([dagger]) References 123, 124, 130, 132, 134, 139.

Caption: Figure 1. A nonkeratinizing squamous cell carcinoma of the oropharynx associated with human papillomavirus infection (hematoxylin-eosin, original magnification X200).

Caption: Figure 2. A, p16 immunostaining of this oropharyngeal, nonkeratinizing squamous cell carcinoma, which was associated with human papillomavirus (HPV) infection. B, High-risk HPV is demonstrated by in situ hybridization of this oropharyngeal squamous cell carcinoma (original magnification X200 [A]; original magnification X200 [B]).

Caption: Figure 3. A, This differentiated nasopharyngeal squamous cell carcinoma shows obvious epithelial growth. B, This undifferentiated nasopharyngeal carcinoma would be impossible to distinguish from other types of high-grade malignancies with only routine stains (hematoxylin-eosin, original magnifications X200 [A] and X400 [B]).

Caption: Figure 4. A, The surface of this verrucous carcinoma appears warty. B, The base of this verrucous carcinoma has invaded with broad tongues of squamous epithelium (hematoxylin-eosin, original magnifications XI00 [A and B]).

Caption: Figure 5. A, Spindle cell carcinoma appears mesenchymal because it is composed predominately of malignant spindled cells. B, p63 expression in a spindle cell carcinoma (hematoxylin-eosin, original magnification X400 [A]; original magnification X400 [B]).

Caption: Figure 6. Acantholytic squamous cell carcinomas often appear vascular (hematoxylin-eosin, original magnification X200).

Caption: Figure 7. A, Some adenosquamous carcinomas have abundant intracellular mucus. B, Other adenosquamous carcinomas have columnar cells that form glandlike structures (hematoxylin-eosin, original magnifications X400 [A] and X200 [B]).

Caption: Figure 8. This basaloid squamous cell carcinoma is associated with overlying squamous cell carcinoma in situ (hematoxylin-eosin, original magnification X200).

Caption: Figure 9. Numerous papillary fronds covered by dysplastic squamous epithelium in papillary squamous cell carcinoma (hematoxylin-eosin, original magnification X100).

Caption: Figure 10. A, This sinonasal nuclear protein in testis (NUT) midline carcinoma is composed mostly of sheets of undifferentiated cells. B, Break-apart fluorescence in situ hybridization for the NUT gene shows one intact and one broken signal in each nucleus of this NUT midline carcinoma (hematoxylin-eosin, original magnification X400 [A]; glycerin immersion, original magnification X150 [B]).
COPYRIGHT 2014 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Shah, Akeesha A.; Jeffus, Susanne K.; Stelow, Edward B.
Publication:Archives of Pathology & Laboratory Medicine
Date:Jun 1, 2014
Words:12857
Previous Article:Breast Implant-Associated Anaplastic Large Cell Lymphoma: Review of a Distinct Clinicopathologic Entity.
Next Article:Fatal Spontaneous Clostridium septicum Gas Gangrene: A Possible Association With Iatrogenic Gastric Acid Suppression.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters